{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:17:37Z","timestamp":1790198257652,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the safety and effectiveness of baloxavir marboxil (baloxavir) and oseltamivir in pediatric influenza patients in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients filling a prescription for baloxavir or oseltamivir within 48\u2005h following an influenza-related outpatient visit were identified in Children's Hospital of Fudan University in China between March 2023 and December 2023. Outcomes were assessed after antiviral treatment and included the incidence of adverse reactions and the duration of fever and other flu symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1430 patients infected with influenza A were collected and 865 patients (baloxavir: <jats:italic>n<\/jats:italic>\u2009=\u2009420; oseltamivir: <jats:italic>n<\/jats:italic>\u2009=\u2009445) finally included. The incidence of adverse reactions of nausea and vomiting was significantly different between the baloxavir group (2.38%) and the oseltamivir group (12.13%) [<jats:italic>P\u2009<\/jats:italic>&amp;lt;\u20090.001, OR\u2009=\u20094.2526, 95%CI (2.0549, 9.6080)]. No differences in other adverse reactions were observed between the two groups. The mean duration of fever in baloxavir group (1.43d) was significantly shorter than that in oseltamivir group (2.31d) [<jats:italic>P\u2009<\/jats:italic>&amp;lt;\u20090.001, 95%CI (0.7815, 0.9917)]. There were no differences in the mean duration of nasal congestion and runny nose, sore throat, cough, and muscle soreness between two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The incidence of nausea and vomiting is lower with baloxavir compared to oseltamivir, and the duration for complete fever reduction is shorter with baloxavir than with oseltamivir. The results indicate that baloxavir is well tolerated and effective in Chinese children.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1418321","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T04:35:46Z","timestamp":1722227746000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and effectiveness of baloxavir marboxil and oseltamivir for influenza in children: a real-world retrospective study in China"],"prefix":"10.3389","volume":"12","author":[{"given":"Xilin","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/cid\/cix1060","article-title":"Seasonal incidence of symptomatic influenza in the United States","volume":"66","author":"Tokars","year":"2018","journal-title":"Clin Infect Dis"},{"key":"B2","volume-title":"Disease Burden of Influenza","year":"2024"},{"key":"B3","volume-title":"Flu Symptoms and Complications","year":"2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1183\/09031936.00186214","article-title":"Influenza virus-induced lung injury: pathogenesis and implications for treatment","volume":"45","author":"Herold","year":"2015","journal-title":"Eur Respir J"},{"key":"B5","volume-title":"People at Higher Risk of Developing Serious flu-Related Complications","year":"2021"},{"key":"B6","doi-asserted-by":"publisher","first-page":"f5061","DOI":"10.1136\/bmj.f5061","article-title":"Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis","volume":"347","author":"Mertz","year":"2013","journal-title":"Br Med J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0140-6736(17)30129-0","article-title":"Influenza","volume":"390","author":"Paules","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3389\/fmicb.2017.01041","article-title":"Secondary bacterial infections associated with influenza pandemics","volume":"8","author":"Morris","year":"2017","journal-title":"Front Microbiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/21645515.2017.1338547","article-title":"Factors affecting immune responses to the influenza vaccine","volume":"14","author":"Castrucci","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00431-013-2023-6","article-title":"The burden of seasonal and pandemic influenza in infants and children","volume":"173","author":"Ruf","year":"2014","journal-title":"Eur J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e20172918","DOI":"10.1542\/peds.2017-2918","article-title":"Influenza-associated pediatric deaths in the United States, 2010\u20132016","volume":"141","author":"Shang","year":"2018","journal-title":"Pediatrics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.pcl.2017.03.007","article-title":"Influenza: a global perspective","volume":"64","author":"Rotrosen","year":"2017","journal-title":"Pediatr Clin North Am"},{"key":"B13","first-page":"684","article-title":"Risk factors of influenza transmission in households","volume":"54","author":"Viboud","year":"2004","journal-title":"Br J Gen Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s12879-018-3548-0","article-title":"The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09","volume":"18","author":"MacIntyre","year":"2018","journal-title":"BMC Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/cid\/ciy874","article-title":"Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20420","article-title":"Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data","volume":"20","author":"Heneghan","year":"2016","journal-title":"Health Technol Assess"},{"key":"B17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1590\/1516-3180.20141324t2","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","volume":"132","author":"Toniolo Neto","year":"2014","journal-title":"Sao Paulo Med J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1093\/jac\/dkx271","article-title":"Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and\/or meta-analyses","volume":"72","author":"Doll","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1080\/03007995.2016.1176016","article-title":"Effects of antiviral treatment on influenza-related complications over four influenza seasons: 2006\u20132010","volume":"32","author":"Spagnuolo","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"B20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/cis636","article-title":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09","volume":"55","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/cid\/ciz908","article-title":"Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes","volume":"71","author":"Hirotsu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0891-5520(05)70406-2","article-title":"Influenza","volume":"12","author":"Cox","year":"1998","journal-title":"Infect Dis Clin North Am"},{"key":"B27","first-page":"26","article-title":"Clinical features of influenza","volume":"7","author":"Nicholson","year":"1992","journal-title":"Semin Respir Infect"},{"key":"B28","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/INF.0000000000002747","article-title":"Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2)","volume":"39","author":"Baker","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1292735","DOI":"10.3389\/fmicb.2023.1292735","article-title":"Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China","volume":"14","author":"Liao","year":"2023","journal-title":"Front Microbiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"a038687","DOI":"10.1101\/cshperspect.a038687","article-title":"Influenza polymerase inhibitors: mechanisms of action and resistance","volume":"11","author":"Takashita","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1093\/infdis\/jiab196","article-title":"Detection of variants with reduced baloxavir marboxil and oseltamivir susceptibility in children with influenza A during the 2019\u20132020 influenza season","volume":"224","author":"Sato","year":"2021","journal-title":"J Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir marboxil for prophylaxis against influenza in household contacts","volume":"383","author":"Ikematsu","year":"2020","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/AAC.03947-14","article-title":"Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro","volume":"59","author":"Belardo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"105126","DOI":"10.1016\/j.antiviral.2021.105126","article-title":"Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model","volume":"193","author":"Park","year":"2021","journal-title":"Antiviral Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/v12070703","article-title":"Combinatory treatment with oseltamivir and itraconazole targeting both virus and host factors in influenza A virus infection","volume":"12","author":"Schloer","year":"2020","journal-title":"Viruses"},{"key":"B36","doi-asserted-by":"publisher","first-page":"611958","DOI":"10.3389\/fmicb.2021.611958","article-title":"Improved in vitro efficacy of baloxavir marboxil against influenza A virus infection by combination treatment with the MEK inhibitor ATR-002","volume":"12","author":"Hamza","year":"2021","journal-title":"Front Microbiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3390\/v12101139","article-title":"In vitro combinations of baloxavir acid and other inhibitors against seasonal influenza A viruses","volume":"12","author":"Checkmahomed","year":"2020","journal-title":"Viruses"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0105622","DOI":"10.1128\/mbio.01056-22","article-title":"Effect of baloxavir and oseltamivir in combination on infection with influenza viruses with PA\/I38T or PA\/E23K substitutions in the ferret model","volume":"13","author":"Koszalka","year":"2022","journal-title":"mBio"},{"key":"B39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/ph15020212","article-title":"Repurposing antifungals for host-directed antiviral therapy?","volume":"15","author":"Schloer","year":"2022","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1418321\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T04:35:50Z","timestamp":1722227750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1418321\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":39,"alternative-id":["10.3389\/fped.2024.1418321"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1418321","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"article-number":"1418321"}}